keyword
https://read.qxmd.com/read/36979900/efficacy-of-serotonin-and-dopamine-activity-modulators-in-the-treatment-of-negative-symptoms-in-schizophrenia-a-rapid-review
#21
REVIEW
Claudio Brasso, Gianluca Colli, Rodolfo Sgro, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Vincenzo Villari, Paola Rocca
Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms (NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the disorder, and their treatment is difficult and rarely specifically investigated. Serotonin-dopamine activity modulators (SDAMs), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce NS. The aim of this rapid review is to summarize the evidence on this topic to make it readily available for psychiatrists treating NS and for further research...
March 16, 2023: Biomedicines
https://read.qxmd.com/read/36979224/application-of-antipsychotic-drugs-in-mood-disorders
#22
REVIEW
Janusz K Rybakowski
Since their first application in psychiatry seventy years ago, antipsychotic drugs, besides schizophrenia, have been widely used in the treatment of mood disorders. Such an application of antipsychotics is the subject of this narrative review. Antipsychotic drugs can be arbitrarily classified into three generations. First-generation antipsychotics (FGAs), such as phenothiazines and haloperidol, were mainly applied for the treatment of acute mania, as well as psychotic depression when combined with antidepressants...
February 27, 2023: Brain Sciences
https://read.qxmd.com/read/36979208/brexpiprazole-pharmacologic-properties-and-use-in-schizophrenia-and-mood-disorders
#23
REVIEW
Marcin Siwek, Krzysztof Wojtasik-Bakalarz, Anna Julia Krupa, Adrian Andrzej Chrobak
In 2002, the first III generation antipsychotic drug was registered-aripiprazole. Its partial dopaminergic agonism underlies its unique mechanism of action and the potentially beneficial influence on the positive, negative, or cognitive symptoms. Due to its relatively high intrinsic activity, the drug could often cause agitation, anxiety, or akathisia. For this reason, efforts were made to develop a drug which would retain the positive favorable actions of aripiprazole but present a more advantageous clinical profile...
February 25, 2023: Brain Sciences
https://read.qxmd.com/read/36927059/association-between-long-term-use-of-prolactin-elevating-antipsychotics-in-women-and-the-risk-of-breast-cancer-what-are-the-clinical-implications
#24
JOURNAL ARTICLE
Judith D Hope, Nicholas A Keks, David L Copolov
BACKGROUND: Some antipsychotic drugs elevate prolactin, and hyperprolactinaemia is associated with an increased risk of breast cancer. Women with schizophrenia have an increased incidence of breast cancer, but also multiple risk factors for the condition. METHOD: This paper will critically review recent epidemiological studies concerning antipsychotics and breast cancer from a psychiatric perspective. RESULTS: Two recent epidemiological studies have found an association between use of prolactin-elevating antipsychotics and breast cancer in women with schizophrenia and other psychotic disorders...
April 2023: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://read.qxmd.com/read/36897762/a-case-of-oral-cenesthopathy-treated-with-the-combination-of-brexpiprazole-and-mirtazapine
#25
JOURNAL ARTICLE
Yojiro Umezaki, Haruhiko Motomura, Rui Egashira, Akira Toyofuku, Toru Naito
OBJECTIVES: Oral cenesthopathy is an uncomfortable and bizarre oral sensation without corresponding organic findings. Although some treatment options, including antidepressants and antipsychotic drugs, have been reported to be effective, the condition remains refractory. Here, we report a case of oral cenesthopathy treated with brexpiprazole, a recently approved D2 partial agonist. METHODS AND RESULTS: A 57-year-old woman presented with a complained of softened incisors...
March 10, 2023: Clinical Neuropharmacology
https://read.qxmd.com/read/36873203/the-pharmacogenetics-of-the-new-generation-antipsychotics-a-scoping-review-focused-on-patients-with-severe-psychiatric-disorders
#26
REVIEW
Octavian Vasiliu
Exploring the possible correlations between gene variations and the clinical effects of the new-generation antipsychotics is considered essential in the framework of personalized medicine. It is expected that pharmacogenetic data will be useful for increasing the treatment efficacy, tolerability, therapeutic adherence, functional recovery, and quality of life in patients with severe psychiatric disorders (SPD). This scoping review investigated the available evidence about the pharmacokinetics, pharmacodynamics, and pharmacogenetics of five new-generation antipsychotics, i...
2023: Frontiers in Psychiatry
https://read.qxmd.com/read/36855876/pharmacotherapies-for-treatment-resistant-depression-how-antipsychotics-fit-in-the-rapidly-evolving-therapeutic-landscape
#27
REVIEW
Manish K Jha, Sanjay J Mathew
One in three adults with major depressive disorder (MDD) do not experience clinically significant improvement after multiple sequential courses of antidepressants and have treatment-resistant depression (TRD). The presence of TRD contributes to the morbidity and excess mortality associated with MDD and has been linked to significantly increased health care expenses. In the absence of a consensus definition of TRD, this report takes a broad approach by considering inadequate response to one or more courses of antidepressants and focuses on atypical antipsychotics that are approved by the U...
March 1, 2023: American Journal of Psychiatry
https://read.qxmd.com/read/36825499/aripiprazole-brexpiprazole-and-cariprazine-can-affect-milk-supply-advice-to-breastfeeding-mothers
#28
JOURNAL ARTICLE
Sharna Naughton, Kate O'Hara, Jarren Nelson, Philip Keightley
OBJECTIVE: We sought to review the effects of Dopamine Receptor Partial Agonist (DRPA) antipsychotic medications on milk supply and breastfeeding. METHOD: Narrative review of selected literature including animal and human data. RESULTS: Scant case study evidence suggests that DRPAs may lead to reduced milk supply for some. CONCLUSIONS: Women taking DRPAs should be advised of the possibility that these may affect milk supply, and reporting should be encouraged to aid future research...
February 24, 2023: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://read.qxmd.com/read/36789916/comparison-of-antipsychotic-dose-equivalents-for-acute-bipolar-mania-and-schizophrenia
#29
JOURNAL ARTICLE
Chia-Ling Yu, Andre F Carvalho, Trevor Thompson, Tzu-Cheng Tsai, Ping-Tao Tseng, Chih-Wei Hsu, Tien-Wei Hsu, Chih-Sung Liang
QUESTION: Are antipsychotic dose equivalents between acute mania and schizophrenia the same? STUDY SELECTION AND ANALYSIS: Six databases were systematically searched (from inception to 17 September 2022) to identify blinded randomised controlled trials (RCTs) that used a flexible-dose oral antipsychotic drug for patients with acute mania. The mean and SD of the effective dose and the pre-post changes in manic symptoms were extracted. A network meta-analysis (NMA) under a frequentist framework was performed to examine the comparative efficacy between the antipsychotics...
February 2023: BMJ Ment Health
https://read.qxmd.com/read/36762866/a-descriptive-study-of-aripiprazole-brexpiprazole-and-cariprazine-exposures-in-children-ages-0-to-5-years-reported-to-united-states-poison-centers
#30
JOURNAL ARTICLE
Nicholas Husak, Thomas W Laudone, James B Leonard
INTRODUCTION: Increased prescribing of antipsychotics and availability of new antipsychotics has resulted in increased exposures in children. Current data on aripiprazole, brexpiprazole, and cariprazine are limited. METHODS: This was a retrospective database study utilizing the National Poison Data System from 2015 through 2021. We included cases of single substance exposures to aripiprazole, brexpiprazole, cariprazine, or lumateperone in children ages 0 to 5 years old with follow-up to a known outcome...
February 10, 2023: Clinical Toxicology
https://read.qxmd.com/read/36637685/agonistic-properties-of-a-series-of-psychotropic-drugs-at-5-ht-1a-receptors-in-rat-and-human-brain-membranes-determined-by-35-s-gtp%C3%AE-s-binding-assay
#31
JOURNAL ARTICLE
Yuji Odagaki, Masaki Mikami, Masakazu Kinoshita, J Javier Meana, Luis F Callado, Jesús A García-Sevilla, Dasiel Oscar Borroto-Escuela, Kjell Fuxe
BACKGROUND: Many psychoactive compounds have been developed to have more beneficial clinical efficacy than conventional drugs by adding agonistic action at 5-HT1A receptors. The aim of the present study was to evaluate several psychotropic drugs that had been reported to behave as an agonist at 5-HT1A receptor (aripiprazole, brexpiprazole, asenapine, lurasidone, and vortioxetine) in both rat and postmortem human brain membranes. METHODS: The [35 S]GTPγS binding assay for Gi/o proteins coupled with 5-HT1A receptors was performed in rat brain membranes and postmortem human brain membranes...
January 13, 2023: Pharmacological Reports: PR
https://read.qxmd.com/read/36523870/third-generation-antipsychotics-in-patients-with-schizophrenia-and-non-responsivity-or-intolerance-to-clozapine-regimen-what-is-the-evidence
#32
REVIEW
Octavian Vasiliu
Clozapine is considered « the golden standard » for the management of treatment-resistant schizophrenia, but many patients do not present adequate responsivity even to this antipsychotic. If we add the need to strictly monitor the hematologic and cardiometabolic adverse events during each clozapine trial and the difficulty of preserving therapeutic adherence in patients with low insight, residual negative/positive symptoms, or economic challenges, then the necessity of exploring alternative interventions for these patients becomes obvious...
2022: Frontiers in Psychiatry
https://read.qxmd.com/read/36517664/mortality-in-patients-with-parkinson-s-disease-related-psychosis-treated-with-pimavanserin-compared-with-other-atypical-antipsychotics-a-cohort-study
#33
JOURNAL ARTICLE
J Bradley Layton, Joan Forns, Lisa J McQuay, Heather E Danysh, Colleen Dempsey, Mary S Anthony, Mary Ellen Turner
INTRODUCTION: Pimavanserin is approved in the USA to treat hallucinations and delusions associated with Parkinson's disease psychosis (PDP). OBJECTIVES: We evaluated mortality in patients with PDP after initiation of pimavanserin or comparator atypical antipsychotics, overall, over time, and across subgroups. METHODS: A cohort of patients aged ≥65 years in the USA with PDP newly initiating pimavanserin or a comparator atypical antipsychotic (clozapine, quetiapine, risperidone, olanzapine, aripiprazole, brexpiprazole) was identified in 2016-2019 Medicare claims data...
February 2023: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://read.qxmd.com/read/36515735/antipsychotics-and-risk-of-qt-prolongation-a-pharmacovigilance-study
#34
JOURNAL ARTICLE
Constance Bordet, Philippe Garcia, Francesco Salvo, Anthony Touafchia, Michel Galinier, Agnès Sommet, François Montastruc
RATIONALE: While meta-analyses of clinical trials found that lurasidone and partial dopamine agonists (brexpiprazole and aripiprazole) were the antipsychotics less likely to cause QTc prolongation, and sertindole, amisulpride, and ziprasidone were the most frequently associated with this adverse drug reaction; no real-world studies have investigated this risk between the different antipsychotics. OBJECTIVES AND METHODS: Using data recorded from 1967 to 2019 in VigiBase®, the World Health Organization's Global Individual Case Safety Reports database, we performed disproportionality analysis to investigate the risk of reporting QT prolongation between 20 antipsychotics...
January 2023: Psychopharmacology
https://read.qxmd.com/read/36495086/dopamine-partial-agonists-a-discrete-class-of-antipsychotics
#35
REVIEW
David Taylor, Ramalingam Chithiramohan, Jasdev Grewal, Avirup Gupta, Lars Hansen, Gavin P Reynolds, Sofia Pappa
Worldwide, there are now three marketed dopamine D2 partial agonists: aripiprazole, brexpiprazole and cariprazine. These three drugs share a number of properties other than their action at D2 receptors. Pharmacologically, they are 5HT2 antagonists and D3 and 5HT1A partial agonists but with little or no alpha-adrenergic, anticholinergic or antihistaminic activity. They also share a long duration of action. Clinically, D2 partial agonists are effective antipsychotics and generally have useful antimanic and antidepressant activity...
December 10, 2022: International Journal of Psychiatry in Clinical Practice
https://read.qxmd.com/read/36436204/exploring-the-underlying-mechanisms-of-drug-induced-impulse-control-disorders-a-pharmacovigilance-pharmacodynamic-study
#36
JOURNAL ARTICLE
Michele Fusaroli, Valentina Giunchi, Vera Battini, Michele Gringeri, Roberto Rimondini, Marco Menchetti, Sonia Radice, Marco Pozzi, Maria Nobile, Emilio Clementi, Fabrizio De Ponti, Carla Carnovale, Emanuel Raschi, Elisabetta Poluzzi
INTRODUCTION: Impulse control disorders (e.g. pathological gambling, hypersexuality) may develop as adverse reactions to drugs. Pathogenetic hypotheses have mainly focused on D3-receptor agonism, and switching to alternatives with different pharmacologic mechanisms represents a common management strategy. Nonetheless, treatment failure is common and gaining pathophysiological insights is needed. AIM: We aimed to identify targets potentially contributing to pathologic impulsivity...
March 2023: Psychiatry and Clinical Neurosciences
https://read.qxmd.com/read/36142523/new-atypical-antipsychotics-in-the-treatment-of-schizophrenia-and-depression
#37
REVIEW
Jolanta Orzelska-Górka, Joanna Mikulska, Anna Wiszniewska, Grażyna Biała
Schizophrenia and depression are heterogeneous disorders. The complex pathomechanism of the diseases imply that medication responses vary across patients. Many psychotropic drugs are available but achieving optimal therapeutic effect can be challenging. The evidence correlates well with clinical observations, suggesting that new atypical antipsychotic drugs are effective against negative and cognitive symptoms of schizophrenia, as well as against affective symptoms observed in depression. The purpose of this review presents the background and evidence for the use of the new second/third-generation antipsychotics (aripiprazole, cariprazine, lurasidone, asenapine, brexpiprazole, lumateperone, pimavanserin) in treatment of schizophrenia and depression...
September 13, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/36138129/the-impact-of-pharmacological-and-non-pharmacological-interventions-on-physical-health-outcomes-in-people-with-mood-disorders-across-the-lifespan-an-umbrella-review-of-the-evidence-from-randomised-controlled-trials
#38
Giovanni Croatto, Davy Vancampfort, Alessandro Miola, Miriam Olivola, Jess G Fiedorowicz, Joseph Firth, Ovidiu Alexinschi, Marcel A Gaina, Vladimir Makkai, Fernanda Cunha Soares, Leandro Cavaliere, Giorgia Vianello, Brendon Stubbs, Paolo Fusar-Poli, Andre F Carvalho, Eduard Vieta, Samuele Cortese, Jae Il Shin, Christoph U Correll, Marco Solmi
OBJECTIVE: People with mood disorders have increased risk of comorbid medical diseases versus the general population. It is paramount to identify interventions to improve physical health in this population. METHODS: Umbrella review of meta-analyses of randomised controlled trials (RCTs) on pharmacological/non-pharmacological interventions for physical health outcomes/intolerability-related discontinuation in mood disorders (any age). RESULTS: Ninety-seven meta-analyses were included...
September 22, 2022: Molecular Psychiatry
https://read.qxmd.com/read/36045588/visualizing-classification-of-drugs-used-in-psychotic-disorders-a-subway-map-representing-mechanisms-established-classes-and-informal-categories
#39
JOURNAL ARTICLE
Crystal Zhou, David J Nutt, Simon Jc Davies
Drugs used to treat psychotic disorders ('antipsychotics') have been widely used in psychiatry since the introduction of chlorpromazine in the mid-1950s. The categorization of these drugs evolved in a piecemeal way, relying initially on grouping by chemical structure (e.g. phenothiazines, butyrophenones), then by epoch of introduction (e.g. first generation ('conventional') vs second generation ('atypical')). As psychopharmacological expertise has advanced, it has become possible to quantify affinities for each drug in this class for relevant receptors including dopamine D2, 5HT2A, 5HT2C, histamine H1 and others...
September 2022: Journal of Psychopharmacology
https://read.qxmd.com/read/35993319/efficacy-and-acceptability-of-second-generation-antipsychotics-with-antidepressants-in-unipolar-depression-augmentation-a-systematic-review-and-network-meta-analysis
#40
REVIEW
Yushun Yan, Xiao Yang, Min Wang, Boran Chen, Li Yin, Xiaohong Ma
Pharmacological treatment of major depressive disorder is often inefficient, and multiple strategies are used for inadequate response to antidepressants. Second-generation antipsychotics are used as augmentation measures in clinical practice; evidence of their efficacy and acceptability is insufficient, and it remains confusing as to which drug should be selected first. In this systematic review and network meta-analysis, we included randomised controlled trials of second-generation antipsychotics used as adjunctive treatment in patients with suboptimal responses...
September 2022: Psychological Medicine
keyword
keyword
161912
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.